Shanghai Megiddo Biological Pharmaceutical Co., Ltd. from the initial first-generation sequencing service started, gradually extended to high-throughput sequencing, bioinformatics service bioinformatics cloud computing, medical laboratory and bio-medicine. Under the current five subsidiaries: United States and Kyrgyzstan science and technology, information technology Sanger, Megiddo Medical Control, more than Chinese biomedical, Megiddo Institute. Where the United States and Kyrgyzstan are setting up experimental base in Shanghai, Beijing and Guangzhou, sales network throughout the country.

Megiddo organism has first-class sequencing platform (HiSeq2500, HiSeq 4000, MiSeq, ABI 3730XL, ABI 7500) and advanced MS platforms (Q-Exactive, Triple TOF 5600, Obitrap Fusion, QTRAP 5500), specializes in genome sequencing, transcriptome sequencing, metagenomic sequencing, single-cell sequencing, sequencing of the target area, exon sequencing, high-throughput genome sequencing technology services and proteomics, metabolomics and other technical services, but also provides multi-omics solutions that meet various research demand. Megiddo biological building high-performance computing clusters (HPC), the Dell rack-mounted servers, blade servers and lustre parallel file system. Computing capacity of up 29.4Tflops, total memory size is 10TB, high-performance storage capacity of 2PB. For the storage, processing and subsequent analysis of massive biological data to provide a stable, efficient hardware support.